Screener
Integra LifeSciences IART Long-Term Debt
Long-Term Debt at other companies
Other financials
Where this comes from
Reported directly by Integra LifeSciences in its filing.
Tagged under the XBRL concept us-gaap:SecuredLongTermDebt.
The source filing: Integra LifeSciences’s 10-Q, filed July 29, 2026.
- Filed
- Jul 29, 2026, 4:03 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0000917520-26-000058
| Line item | June 30, 2026 | December 31, 2025 |
|---|---|---|
| Accrued compensation | 68,177 | 74,079 |
| Accrued expenses and other current liabilities | 107,618 | 130,493 |
| Total current liabilities | 330,881 | 455,981 |
| Long-term borrowings under senior credit facility | 1,736,105 | 1,729,556 |
| Long-term borrowings under securitization facility | 92,600 | — |
| Lease liability - operating leases | 162,660 | 163,059 |
| Deferred tax liabilities | 3,470 | 5,664 |
| Other liabilities | 194,397 | 204,278 |
Item 1. Financial Statements
FAQ
- What is Integra LifeSciences's long-term debt?
- Integra LifeSciences (IART) reported long-term debt of $1.74B in Q2 2026.
- How has Integra LifeSciences's long-term debt changed year-over-year?
- Integra LifeSciences's long-term debt increased by 55.3% year-over-year, from $1.12B to $1.74B.
- What is the long-term trend for Integra LifeSciences's long-term debt?
- Over 5 years (2020 to 2025), Integra LifeSciences's long-term debt has grown at a 13.1% compound annual growth rate (CAGR), from $933.39M to $1.73B.
- What does long-term debt mean?
- Bonds, term loans, notes payable, and other borrowings with maturities beyond one year — the primary long-term financing source.
Ask your AI about Integra LifeSciences's long-term debt.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude